ArticleJournal of molecular biology2007
Identification and characterization of single chain anti-cocaine catalytic antibodies.
Article in Journal of molecular biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Catalytic Antibody Blunts Carfentanil-Induced Respiratory Depression.ACS pharmacology & translational science · 2023Article
- Immunotherapies for the Treatment of Drug Addiction.Vaccines · 2022Review
- Antibody-Mediated Catalysis in Infection and Immunity.Infection and immunity · 2017Review
- Vaccines against drugs of abuse: where are we now?Therapeutic advances in vaccines · 2014Review
- Future pharmacological treatments for substance use disorders.British journal of clinical pharmacology · 2014Review
- Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.Journal of medicinal chemistry · 2013Article
- Pharmacokinetic strategies for treatment of drug overdose and addiction.Future medicinal chemistry · 2012Review
- Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.Future medicinal chemistry · 2012Review
- Vaccines targeting drugs of abuse: is the glass half-empty or half-full?Nature reviews. Immunology · 2011Review
- Immunopharmacotherapeutic manifolds and modulation of cocaine overdose.Pharmacology, biochemistry, and behavior · 2011Article
- Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- The concept of pharmacologic cocaine interception as a treatment for drug abuse.Chemico-biological interactions · 2010Article
- Anti-cocaine vaccine development.Expert review of vaccines · 2010Review
- Active immunotherapy for the Treatment of Cocaine Dependence.Drugs of the future · 2010Article
- Catalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings.Acta naturae · 2009Article
- Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.Pharmacology, biochemistry, and behavior · 2009Review
- A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2008Article
- Antibody-mediated prevention of Fusarium mycotoxins in the field.International journal of molecular sciences · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cocaine is a powerful and addictive stimulant whose abuse remains a prevalent health and societal crisis. Unfortunately, no pharmacological therapies exist and therefore alternative protein-based therapies have been examined. One such approach is immunopharmacotherapy, wherein antibodies are utilized to either bind or hydrolyze cocaine thereby blocking it from exerting its euphoric effect. Towards this end, antibodies capable of binding and hydrolyzing cocaine were identified by phage display from a biased single chain antibody library generated from the spleens of mice previously immunized with a cocaine phosphonate transition state analog hapten. Two classes of antibodies emerged based on sequence homology and mode of action. Alanine scanning mutagenesis and kinetic analysis revealed that residues H97, H99, and L96 are crucial for antibodies 3F5 and 3H9 to accelerate the hydrolysis of cocaine. Antibodies 3F1 through 3F4, which are similar to our previously identified 3A6 class of antibodies, catalyze hydrolysis through transition state stabilization by tyrosine or histidine residues H50 and L94. Mutation of either one or both tyrosine residues to histidine conferred hydrolytic activity on previously inactive antibody 3F4. Mutational analysis of residue H50 of antibody 3F3 resulted in a glutamine mutant with a rate enhancement three times greater than wild-type. A double mutant, containing glutamineH50 and lysineH52, showed a tenfold rate enhancement over wild-type. These results indicate the power of initial selection of catalytic antibodies from a biased antibody library in both rapid generation and screening of mutants for improved catalysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.